Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Vitamin D Metabolism Parameters and Cytokine Profile in COVID-19 Patients with Bolus Cholecalciferol Supplementation.

Author information

Affiliations

  • 1. Almazov National Medical Research Centre, 2, Akkuratov Str., St. Petersburg 197341, Russia.
      Authors
    • Karonova TL 1
    • Mikhaylova AA 1
    • Golovatyuk KA 1
    • Chernikova AT 1
    • Starshinova AA 1
    • Shlyakhto EV 1
    (6 authors)
  • 2. Saint Petersburg Pasteur Institute, Saint-Petersburg 197101, Russia.
      Authors
    • Korobova ZR 2
    • Liubimova NE 2
    • Totolian AA 2
    (3 authors)
  • 3. Department of Pharmacognosy and Industrial Pharmacy, Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow 119991, Russia.
      Authors
    • Kudlay DA 3
    (1 author)

ORCIDs linked to this article

Diagnostics (Basel, Switzerland), 02 Jul 2024, 14(13):1408
https://doi.org/10.3390/diagnostics14131408 PMID: 39001298 

Abstract 

Recent studies have demonstrated the relationship between vitamin D deficiency, infection severity and mortality from COVID-19. This study aimed to analyze the vitamin D metabolites and cytokine expression levels of COVID-19 patients who were hospitalized with bolus cholecalciferol supplementation.

Materials and methods

This study represents the next stage of the open-label randomized pilot conducted by the Almazov National Medical Research Centre. A total of 44 hospitalized patients, comparable in demographic, clinical, laboratory and instrumental baseline characteristics, with moderate/severe COVID-19 were included. All patients had similar doses of concomitant corticosteroid therapy. Twenty-two patients received 50,000 IU cholecalciferol on the first and eighth days of hospitalization. The serum 25(OH)D, 1,25(OH)2D and 28 plasma cytokines were estimated for each group initially and on the ninth day of hospitalization.

Results

Initially, there were no differences in the 1,25(OH)2D and cytokine levels in patients with vitamin D deficiency and normal 25(OH)D. Bolus cholecalciferol therapy at a total dose of 100,000 IU led to an increase in 25(OH)D levels in hospitalized patients with COVID-19, while the levels of the active metabolite (1,25(OH)2D) did not show significant differences between the groups or in its increased level over time, regardless of cholecalciferol supplementation. Furthermore, cholecalciferol supplementation at a total dose of 100,000 IU did not affect the majority of the cytokines estimated on the ninth day of hospitalization, except for the pro-inflammatory marker IL-1b, the concentration of which was lower in the group of patients without vitamin D supplementation.

Conclusions

The 25(OH)D level was positively associated with an anti-inflammatory immune response, but cholecalciferol supplementation at a total dose of 100,000 IU did not affect the active-form vitamin D or cytokine expression levels. This fact may be explained by the impact of corticosteroid therapy, and it requires further investigation in a post-COVID-19 context.

Full text links 

Read article at publisher's site: https://doi.org/10.3390/diagnostics14131408

References 

Articles referenced by this article (30)

Show 10 more references (10 of 30)

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Federal Almazov North-West Medical Research Centre (1)